Citius Oncology, Inc. (Nasdaq: CTOR) has announced a commercial update regarding the U.S. launch of LYMPHIR™ (denileukin diftitox-cxdl), a targeted immune therapy for cutaneous T-cell lymphoma (CTCL). The company reported significant early adoption metrics, indicating a positive trajectory for the drug's market entry. Key highlights include a sequential growth in orders from target institutions, with initial accounts placing repeat orders, suggesting a strong continuity in prescribing practices. Notably, 83% of targeted accounts have either added or are actively progressing LYMPHIR through formulary reviews, demonstrating robust institutional uptake. Furthermore, Citius has secured broad market access with approximately 135 health plans covering around 80% of lives, and no reported reimbursement denials or prior authorization barriers have been encountered. The company is also witnessing increasing demand for clinical education and in-services, which are critical for supporting the drug's integration into treatment protocols. Citius Oncology's Chairman and CEO, Leonard Mazur, expressed optimism about the early commercial indicators, emphasizing the potential for LYMPHIR to become a key player in the CTCL treatment landscape and possibly in combination therapies for other cancers. The company is advancing clinical development through collaborations with leading academic centers, further validating LYMPHIR's efficacy and expanding its application in oncology. Overall, these developments position Citius Oncology favorably for continued growth and market penetration.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.